Cancer remains a formidable threat to the lives of millions of Americans; one of every four deaths in the U.S. is from cancer with about 1.5 million new cases diagnosed each year. Yet, the number of deaths from common solid tumors of adults has not decreased significantly in the past 30 years. Given this history, recent studies demonstrating the potential of new drugs that target tumor blood vessel growth (angiogenesis) are particularly exciting. Now that several of these anti-angiogenic agents are entering clinical trials (e.g., endostatin) an assessment of their ability to inhibit angiogenesis is crucial for evaluating their clinical potential. Magnetic resonance imaging (MRI) with contrast agents has the potential to provide a wealth of information relevant to this goal. Yet, many of the current contrast agent methods have proved to be either nonspecific measures of angiogenesis or not clinically applicable. Thus, this research seeks to develop and validate methods that are both clinically applicable and provide angiogenic-specific measurements. We will investigate both relaxivity (T1:
Aim 1) and susceptibility (T2:
Aim 2) contrast agent methods to measure blood volume and vascular morphology. Initial method development and validation will be accomplished in a rat tumor model. Development will include characterizing the biophysical relationships underlying the contrast-agent MRI signal, an approach unique to these studies and relevant to all contrast-agent MRI methods. Taken together this information should enable the rational application of T1 and T2 contrast methods to evaluate angiogenesis in glioma patients (Aim 3), a patient population in desperate need of better therapies. Completion of these studies should move us closer to the ultimate goal of dramatically improving the diagnosis and management of patients with vascular tumors such as gliomas. Thus given the fundamental but clinically relevant nature of these studies, whose results can be applied to the study of all solid tumors, the potential impact of the proposed studies is enormous.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA082500-02
Application #
6362720
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Liu, Guoying
Project Start
2000-03-01
Project End
2003-02-28
Budget Start
2001-03-01
Budget End
2002-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$235,463
Indirect Cost
Name
Medical College of Wisconsin
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
073134603
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Chitambar, Christopher R; Al-Gizawiy, Mona M; Alhajala, Hisham S et al. (2018) Gallium Maltolate Disrupts Tumor Iron Metabolism and Retards the Growth of Glioblastoma by Inhibiting Mitochondrial Function and Ribonucleotide Reductase. Mol Cancer Ther 17:1240-1250
Schmainda, K M; Prah, M A; Rand, S D et al. (2018) Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project. AJNR Am J Neuroradiol 39:1008-1016
Prah, Melissa A; Al-Gizawiy, Mona M; Mueller, Wade M et al. (2018) Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. J Neurooncol 136:13-21
Malyarenko, Dariya; Fedorov, Andriy; Bell, Laura et al. (2018) Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies. J Med Imaging (Bellingham) 5:011006
Newitt, David C; Malyarenko, Dariya; Chenevert, Thomas L et al. (2018) Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network. J Med Imaging (Bellingham) 5:011003
Doan, Ninh B; Nguyen, Ha S; Al-Gizawiy, Mona M et al. (2017) Acid ceramidase confers radioresistance to glioblastoma cells. Oncol Rep 38:1932-1940
Doan, Ninh B; Nguyen, Ha S; Montoure, Andrew et al. (2017) Acid ceramidase is a novel drug target for pediatric brain tumors. Oncotarget 8:24753-24761
Bell, L C; Does, M D; Stokes, A M et al. (2017) Optimization of DSC MRI Echo Times for CBV Measurements Using Error Analysis in a Pilot Study of High-Grade Gliomas. AJNR Am J Neuroradiol 38:1710-1715
Nguyen, H S; Milbach, N; Hurrell, S L et al. (2016) Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. AJNR Am J Neuroradiol 37:2201-2208
McGarry, Sean D; Hurrell, Sarah L; Kaczmarowski, Amy L et al. (2016) Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy. Tomography 2:223-228

Showing the most recent 10 out of 54 publications